Full-Time

Senior Director

Global Brand & Portfolio Management

Updated on 9/3/2026

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

Compensation Overview

$287k - $352k/yr

+ Incentive Compensation + Equity

Summit, NJ, USA + 2 more

More locations: Maidenhead, UK | Waltham, MA, USA

Hybrid

Hybrid role with on-site days in Summit, NJ; Waltham, MA; Maidenhead, UK.

Bachelor's, Master's, MBA

Category
Growth & Marketing (1)
Required Skills
Market Research
Forecasting
Excel/Numbers/Sheets
Financial Modeling
PowerPoint/Keynote/Slides

Get referred to CSL

See people who can refer or advise you

Requirements
  • Bachelor of Science with MBA or MS (Pharmaceutical or basic sciences) preferred
  • Minimum 12 years of experience in the pharmaceutical industry, including at least 8 years of experience in one of the various pharmaceutical functions, e.g. commercial, sales, or marketing, vaccines highly preferred
  • 5+ years in portfolio strategy or multi-brand leadership
  • Minimum 7 years of experience in managing personnel, project management, leading cross-functional global teams
  • Proven success in growing established products, particularly across regions or through global capacity
  • Intercultural experience and ability to lead in a complex and rapidly changing business environment, preferably 7+ years
  • Skills: Strategic framing, evidence strategy, financial modeling, governance design, stakeholder influence, executive communication
  • Strong knowledge of business processes within pharmaceutical industry, e.g. forecasting, strategic planning, budgeting, project management
  • Proficiency in MS Excel and PowerPoint and other Microsoft applications
  • Travel 10-20% - Primarily Global
Responsibilities
  • Global Portfolio Strategy & Brand Leadership: Direct a team responsible for global product strategy across marketed vaccines, pipeline assets, and launch products.
  • Define product portfolio positioning, co-positioning strategies, above-brand narratives, evidence themes, lifecycle priorities, and portfolio investment recommendations.
  • Oversee lifecycle management strategies that drive both short- and long-term growth of commercialized brands.
  • Lead global launch planning and commercialization readiness for pipeline assets, including launch sequencing, business case development, and resource prioritization.
  • Oversees and guides continued global launch planning for aTIVc, including maximizing the portfolio opportunity across Fluad and aTIVc, refining the launch sequencing strategy, advancing business cases for key investments, and leveraging the Glocal brand marketing model (global to local division of activities) to drive efficiencies.
  • Direct geographic expansion strategies and evaluate market entry and exit opportunities across the portfolio.
  • Provide portfolio and commercial input into long-term pricing strategies, value propositions, and market access planning in partnership with Global Market Access & Pricing for both inline and pipeline products
  • Support evaluation of external partnerships, business development opportunities, and portfolio expansion opportunities which are led by GCS&P’s External Partnerships team.
  • Oversee development and continuous improvement of global claims, messaging, communications, and scientific narratives.
  • Ensure product portfolio strategies are informed by market research, competitive intelligence, customer insights, epidemiological trends, and evolving vaccine market dynamics.
  • Manage team budgets and identify opportunities to improve operational efficiency and return on investment.
  • Portfolio Development, Strategic Decision-Making & Governance: Lead the commercial evaluation and strategic development of internal vaccine programs from early development through commercialization in partnership with R&D, GCS&P’s Strategy & Business Planning team, GCS&P’s External Partnerships team and various cross-functional team members.
  • Direct assessment of key development milestones, including clinical strategy, evidence requirements, comparator selection, timing, and commercial readiness.
  • Identify portfolio opportunities, risks, data gaps, and investment priorities; guide cross-functional teams in developing plans to address them.
  • Support and/or lead governance processes and planning forums to ensure timely decision-making, transparency, accountability, and strategic alignment.
  • Uphold portfolio-level decision frameworks, escalation pathways, and implementation roadmaps for strategic priorities.
  • Develop and advance business cases for major internal product investments, clinical development programs, and portfolio expansion opportunities, partnering with regions/markets and cross-functional team members.
  • Influence senior leadership on prioritization, resource allocation, funding decisions, and long-range investment strategies.
  • Represent the commercial function in governance forums and ensure Seqirus business unit priorities are reflected in CSL enterprise strategic decisions.
  • Own or oversee relevant global commercial governance processes and continuous improvement initiatives.
  • Cross-Functional Leadership, Alignment & Value Optimization: Oversee and/or lead cross-functional and global brand team governance across commercial, R&D (regulatory, clinical development, medical affairs), CEA, finance, operations and supply chain, and external partnerships/business development stakeholders.
  • Align regional and functional strategies with overall portfolio objectives and resolve competing priorities across brands and functions.
  • Lead strategic discussions with global and regional commercial leaders to advance lifecycle opportunities and pipeline development plans.
  • Foster collaboration across regions to ensure consistent execution of portfolio strategies while addressing market-specific needs.
  • Influence senior leaders and cross-functional partners to secure alignment on key commercial and development decisions.
  • Aim to optimize portfolio investment allocation and resource prioritization to maximize mid- to long-term portfolio value and return on investment.
  • Integrate evidence generation, publication planning, and scientific communication strategies to support a unified portfolio narrative.
  • Lead scenario planning, competitive assessments, and risk mitigation efforts across the portfolio.
  • Establish strong partnerships with external agencies, consultants, industry organizations, and key strategic partners.

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FY26 HEMGENIX sales rose 25%, validating CSL’s gene-therapy commercialization engine.
  • CSL completed $176 million in FY26 cost savings, ahead of plan.
  • VarmX’s September 2025 option deal adds a potential $2.1 billion anticoagulation franchise.

What critics are saying

  • FY26 revenue fell 1% and underlying NPATA fell 2% on plasma weakness.
  • China albumin sales dropped 17% in FY26 after government cost-containment measures.
  • Pentagon ended the U.S. flu vaccine mandate in 2026, pressuring Seqirus demand and execution.

What makes CSL unique

  • CSL spans plasma, gene therapy, and influenza vaccines, unlike single-platform biotech peers.
  • HEMGENIX remains the only approved hemophilia B gene therapy across the U.S. and Europe.
  • CSL’s global plasma collection and manufacturing network supports hard-to-replicate immunoglobulin and albumin supply.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Aug 17th, 2026
CSL reports 2% drop in annual profit to $3.14B on weak plasma sales

Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.

Yahoo Finance
May 2nd, 2026
CSL to split Seqirus vaccine unit as shares slide 50% amid restructure and cost cuts

CSL has announced a restructuring plan including the separation of its Seqirus influenza vaccine business into a standalone entity, alongside workforce reductions and plasma collection centre closures. Management cited prolonged margin pressures and operational challenges as drivers for the changes. The announcement follows a sharp share price decline, with CSL trading at A$124.84, down 27.4% year-to-date and 50.1% over the past year. Three-year and five-year returns show declines of 56.3% and 51.0% respectively. The restructuring aims to simplify operations and refocus capital on higher-returning areas. Separating Seqirus could provide clearer visibility into CSL's core plasma and specialty therapies businesses, whilst allowing independent capital allocation decisions. However, investors face execution risks typical of separations of this scale, including one-off charges and operational disruption.

Yahoo Finance
Apr 23rd, 2026
CSL shares hit 2017 low as Pentagon scraps flu vaccine mandate for military personnel

Australian biotech CSL extended losses on Thursday, falling to its lowest level since August 2017, after the US Pentagon scrapped its flu vaccine mandate for military personnel. The stock dropped as much as 0.8%, bringing yearly losses to over 25%. The policy reversal threatens demand from a key institutional buyer, compounding CSL's existing challenges. The company's Seqirus vaccines unit generated $2.17 billion in revenue in fiscal 2025, representing 14% of total revenue. CSL has faced sustained pressure from slowing demand for plasma-derived therapies, higher costs and multiple earnings downgrades. The stock plunged 39% last year, its biggest annual drop since 2002. Analysts cite concerns over falling US flu vaccination rates, weaker Seqirus earnings and delayed strategic plans.

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...